In this section
The publication feed below is often incomplete and out of date; for an up to date summary of our publications please see Google Scholar or Pub Med
@article{Schlott:2018:10.1021/acsinfecdis.7b00203,
author = {Schlott, AC and Holder, AA and Tate, EW},
doi = {10.1021/acsinfecdis.7b00203},
journal = {ACS Infectious Diseases},
pages = {449--457},
title = {N-myristoylation as a drug target in malaria: exploring the role of N-myristoyltransferase substrates in the inhibitor mode of action},
url = {http://dx.doi.org/10.1021/acsinfecdis.7b00203},
volume = {4},
year = {2018}
}
TY - JOUR
AB - Malaria continues to be a significant cause of death and morbidity worldwide, and there is a need for new antimalarial drugs with novel targets. We have focused as a potential target for drug development on N-myristoyl transferase (NMT), an enzyme that acylates a wide range of substrate proteins. The NMT substrates in Plasmodium falciparum include some proteins that are common to processes in eukaryotes such as secretory transport and others that are unique to apicomplexan parasites. Myristoylation facilitates a protein interaction with membranes that may be strengthened by further lipidation, and the inhibition of NMT results in incorrect protein localization and the consequent disruption of function. The diverse roles of NMT substrates mean that NMT inhibition has a pleiotropic and severe impact on parasite development, growth, and multiplication. To study the mode of action underlying NMT inhibition, it is important to consider the function of proteins upstream and downstream of NMT. In this work, we therefore present our current perspective on the different functions of known NMT substrates as well as compare the inhibition of cotranslational myristoylation to the inhibition of known targets upstream of NMT.
AU - Schlott,AC
AU - Holder,AA
AU - Tate,EW
DO - 10.1021/acsinfecdis.7b00203
EP - 457
PY - 2018///
SN - 2373-8227
SP - 449
TI - N-myristoylation as a drug target in malaria: exploring the role of N-myristoyltransferase substrates in the inhibitor mode of action
T2 - ACS Infectious Diseases
UR - http://dx.doi.org/10.1021/acsinfecdis.7b00203
UR - https://www.ncbi.nlm.nih.gov/pubmed/29363940
UR - http://hdl.handle.net/10044/1/58350
VL - 4
ER -
Prof. Ed Tate
GSK Chair in Chemical Biology
Department of Chemistry
Molecular Sciences Research Hub, White City Campus,
82 Wood Lane, London, W12 0BZ
e.tate@imperial.ac.uk
Tel: +44 (0)20 759 + ext 43752 or 45821